Quality of Life in Myeloproliferative Neoplasms Symptoms and Management Implications

被引：11

作者：

Mesa, Ruben ^{[1
]}

Palmer, Jeanne ^{[2
]}

Eckert, Ryan ^{[1
,3
]}

Huberty, Jennifer ^{[1
,3
]}

机构：

[1] UT Hlth San Antonio MD Anderson, Mays Canc Ctr, 7979 Wurzbach Rd, San Antonio, TX 78229 USA

[2] Mayo Clin, Div Hematol & Med Oncol, 5777 East Mayo Blvd, Phoenix, AZ 85054 USA

[3] Arizona State Univ, Coll Hlth Solut, 550 North 3rd St, Phoenix, AZ 85004 USA

来源：

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | 2021年 / 35卷 / 02期

关键词：

Myeloproliferative neoplasm; Quality of life; Inflammation; Integrative medicine; POLYCYTHEMIA-VERA; ESSENTIAL THROMBOCYTHEMIA; ASSESSMENT FORM; AVAILABLE THERAPY; CLONAL EVOLUTION; MYELOFIBROSIS; RUXOLITINIB; BURDEN; MOMELOTINIB; DISEASE;

D O I：

10.1016/j.hoc.2020.12.006

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

include essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF). These disorders share biological underpinnings with somatic mutation-driven myeloproliferation, risk of thrombotic events, risk of hemorrhagic events, potential splenomegaly, possible cytopenias (either disease and/or therapy toxicity related), potential progression (from ET/PV to MF) or to acute myeloid leukemia (acute myeloid leukemia or MPN blast phase). Importantly, in addition to this range of burdens that patients with MPN can experience, they can also experience significant diseaserelated symptoms such as fatigue, vascular symptoms (headaches, difficulties with

引用

页码：375 / 390

页数：16

共 37 条

[1] Momelotinib inhibits ACVR1/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents [J].

Asshoff, Malte ;

Petzer, Verena ;

Warr, Matthew R. ;

Haschka, David ;

Tymoszuk, Piotr ;

Demetz, Egon ;

Seifert, Markus ;

Posch, Wilfried ;

Nairz, Manfred ;

Maciejewski, Pat ;

Fowles, Peter ;

Burns, Christopher J. ;

Smith, Gregg ;

Wagner, Kay-Uwe ;

Weiss, Guenter ;

Whitney, J. Andrew ;

Theurl, Igor .

BLOOD, 2017, 129 (13) :1823-1830

[2] Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early/prefibrotic primary myelofibrosis [J].

Barbui, Tiziano ;

Thiele, Juergen ;

Carobbio, Alessandra ;

Passamonti, Francesco ;

Rumi, Elisa ;

Randi, Maria Luigia ;

Bertozzi, Irene ;

Vannucchi, Alessandro M. ;

Gisslinger, Heinz ;

Gisslinger, Bettina ;

Finazzi, Guido ;

Ruggeri, Marco ;

Rodeghiero, Francesco ;

Rambaldi, Alessandro ;

Gangat, Naseema ;

Tefferi, Ayalew .

BLOOD, 2012, 120 (03) :569-571

[3] How We Design Feasibility Studies [J].

Bowen, Deborah J. ;

Kreuter, Matthew ;

Spring, Bonnie ;

Cofta-Woerpel, Ludmila ;

Linnan, Laura ;

Weiner, Diane ;

Bakken, Suzanne ;

Kaplan, Cecilia Patrick ;

Squiers, Linda ;

Fabrizio, Cecilia ;

Fernandez, Maria .

AMERICAN JOURNAL OF PREVENTIVE MEDICINE, 2009, 36 (05) :452-457

[4] Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs [J].

Emanuel, Robyn M. ;

Dueck, Amylou C. ;

Geyer, Holly L. ;

Kiladjian, Jean-Jacques ;

Slot, Stefanie ;

Zweegman, Sonja ;

te Boekhorst, Peter A. W. ;

Commandeur, Suzan ;

Schouten, Harry C. ;

Sackmann, Federico ;

Kerguelen Fuentes, Ana ;

Hernandez-Maraver, Dolores ;

Pahl, Heike L. ;

Griesshammer, Martin ;

Stegelmann, Frank ;

Doehner, Konstanze ;

Lehmann, Thomas ;

Bonatz, Karin ;

Reiter, Andreas ;

Boyer, Francoise ;

Etienne, Gabriel ;

Ianotto, Jean-Christophe ;

Ranta, Dana ;

Roy, Lydia ;

Cahn, Jean-Yves ;

Harrison, Claire N. ;

Radia, Deepti ;

Muxi, Pablo ;

Maldonado, Norman ;

Besses, Carlos ;

Cervantes, Francisco ;

Johansson, Peter L. ;

Barbui, Tiziano ;

Barosi, Giovanni ;

Vannucchi, Alessandro M. ;

Passamonti, Francesco ;

Andreasson, Bjorn ;

Ferarri, Maria L. ;

Rambaldi, Alessandro ;

Samuelsson, Jan ;

Birgegard, Gunnar ;

Tefferi, Ayalew ;

Mesa, Ruben A. .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (33) :4098-4103

[5] Impact of Inflammation on Myeloproliferative Neoplasm Symptom Development [J].

Geyer, Holly L. ;

Dueck, Amylou C. ;

Scherber, Robyn M. ;

Mesa, Ruben A. .

MEDIATORS OF INFLAMMATION, 2015, 2015

[6] Development of a harmonized patient-reported outcome questionnaire to assess myelofibrosis symptoms in clinical trials [J].

Gwaltney, Chad ;

Paty, Jean ;

Kwitkowski, Virginia E. ;

Mesa, Ruben A. ;

Dueck, Amylou C. ;

Papadopoulos, Elektra J. ;

Wang, Lixia ;

Feliciano, Joseph ;

Coons, Stephen Joel .

LEUKEMIA RESEARCH, 2017, 59 :26-31

[7] Results from a Phase 2 Study of Navitoclax in Combination with Ruxolitinib in Patients with Primary or Secondary Myelofibrosis [J].

Harrison, Claire N. ;

Garcia, Jacqueline S. ;

Mesa, Ruben A. ;

Somervaille, Tim C. P. ;

Komrokji, Rami S. ;

Pemmaraju, Naveen ;

Jamieson, Catriona ;

Papadantonakis, Nikolaos ;

Foran, James M. ;

O'Connell, Casey L. ;

Holes, Leanne ;

Jia, Jia ;

Harb, Jason ;

Hutti, Jessica ;

Prchal, Josef T. .

BLOOD, 2019, 134

[8] Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial [J].

Harrison, Claire N. ;

Vannucchi, Alessandro M. ;

Platzbecker, Uwe ;

Cervantes, Francisco ;

Gupta, Vikas ;

Lavie, David ;

Passamonti, Francesco ;

Winton, Elliott F. ;

Dong, Hua ;

Kawashima, Jun ;

Maltzman, Julia D. ;

Kiladjian, Jean-Jacques ;

Verstovsek, Srdan .

LANCET HAEMATOLOGY, 2018, 5 (02) :E73-E81

[9] Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide [J].

Harrison, Claire N. ;

Mead, Adam J. ;

Panchal, Anesh ;

Fox, Sonia ;

Yap, Christina ;

Gbandi, Emmanouela ;

Houlton, Aimee ;

Alimam, Samah ;

Ewing, Joanne ;

Wood, Marion ;

Chen, Frederick ;

Coppell, Jason ;

Panoskaltsis, Nicki ;

Knapper, Steven ;

Ali, Sahra ;

Hamblin, Angela ;

Scherber, Robyn ;

Dueck, Amylou C. ;

Cross, Nicholas C. P. ;

Mesa, Ruben ;

McMullin, Mary Frances .

BLOOD, 2017, 130 (17) :1889-1897

[10] Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer? [J].

Hasselbalch, Hans Carl .

BLOOD, 2012, 119 (14) :3219-3225

← 1 2 3 4 →